MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Section: Diabetes & Endocrinology
Diabetes & Endocrinology

Differential Gastrointestinal Risks of Opioids in Type 2 Diabetes Patients on GLP-1RA Therapy: A Comparative Analysis

MedXY Editorial TeamSep 15, 2026
opioidstype 2 diabetesglucagon-like peptide-1 receptor agonistsgastrointestinal events

Adults with T 2 D using G L P 1 R A include 411,188 patients from Medicare, MarketScan, and Optum Clinformatics, 2016 to 2025. Exposure groups comprise 100,180 oxycodone, 199,601 hydrocodone, and 111,407 tramadol initiators. Outcomes are severe constipation, bowel obstruction, and gastroparesis. Thirty-day weighted risks are 0.51, 0.35, and 0.33 per cent, respectively. R R values are 1.48, 1.55, and 1.05 with 95 percent CI ranges of 1.30 to 1.69, 1.33 to 1.79, and 0.91 to 1.21.

Highlight

• Oxycodone initiation in adults with type 2 diabetes (T2D) on GLP-1 receptor agonists (GLP-1RAs) is associated with higher short-term risks of severe constipation and bowel obstruction compared to hydrocodone and tramadol.
• Hydrocodone and tramadol show comparable gastrointestinal safety profiles in this patient population.
• No significant differences were observed in gastroparesis risk among the opioids studied.
• Careful opioid selection is crucial to minimize gastrointestinal adverse effects in T2D patients receiving GLP-1RA therapy.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Predicting Type 2 Diabetes Remission and Relapse After Metabolic-Bariatric Surgery and Lifestyle Therapy: Insights from the ARMMS-T2D Study

Diabetes & EndocrinologyOct 29, 2026

Enhancing Glycemic Control in Non-Insulin-Treated Type 2 Diabetes with Continuous Glucose Monitoring: New Evidence from the CONNECT Trial

Diabetes & EndocrinologyOct 24, 2026

HRS-7535: A Promising Oral GLP-1 Receptor Agonist for Type 2 Diabetes Uncontrolled by Metformin and SGLT2 Inhibitors

Diabetes & EndocrinologyOct 19, 2026
Loading comments...

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story